Navigation Links
Closing coal-burning power plant in China and improved cognitive development in children
Date:7/14/2008

July 14, 2008 Closing coal-fired power plants can have a direct, positive impact on children's cognitive development and health according to a study released by the Columbia Center for Children's Environmental Health (CCCEH) at Columbia University's Mailman School of Public Health. The study allowed researchers to track and compare the development of two groups of children born in Tongliang, a city in China's Chongqing Municipality one in utero while a coal-fired power plant was operating in the city and one in utero after the Chinese government had closed the plant. Among the first group of children, prenatal exposure to coal-burning emissions was associated with significantly lower average developmental scores and reduced motor development at age two. In the second unexposed group, these adverse effects were no longer observed; and the frequency of delayed motor developmental was significantly reduced. The study findings are published in the July 14th Environmental Health Perspectives.

"This study provides direct evidence that governmental action to eliminate polluting coal-burning sources benefits children's neurodevelopment," said Frederica Perera, DrPH, professor of Environmental Health Sciences at the Mailman School of Public Health, director of the Columbia Center for Children's Environmental Health, and lead author of the study. "These findings have major implications for environmental health and energy policy as they demonstrate that reduction in dependence on coal for energy can have a measurable positive impact on children's development and health in China and elsewhere."

To conduct the study, researchers from CCCEH partnered with physicians and scientists from the Children's Hospital of Chongqing Medical University, the School of Public Health at Fudan University in Shanghai, and the School of Environmental Science and Engineering at Shanghai Jiao Tong University. The researchers followed two successive cohorts of C
'/>"/>

Contact: Stephanie Berger
sb2247@columbia.edu
212-305-4372
Columbia University's Mailman School of Public Health
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Disclosing violence to primary care or obstetrics/gynecology physicians most beneficial
2. Disclosing violence to primary care or obestetrics/gynecology physicians most beneficial
3. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
4. Mindray to Hold Conference Call to Discuss the Integration Plan and Closing of the Acquisition of Datascope Corp.s Patient Monitoring Business
5. Alcoholism Gender Gap Is Closing
6. Thelen Instrumental in Closing $1 Billion Outsourcing Deal for Client Harvard Pilgrim Health Care
7. MSAs John Ryan III and Bill Lambert to Ring Closing Bell at New York Stock Exchange on Tuesday
8. Andover Medical, Inc. Anticipates Closing $2.0 Million Private Financing
9. Cogdell Spencer Inc. Announces the Closing of the Marshall Erdman and Associates Merger
10. Nerites Corporation Announces Closing of Series A Funding Round
11. Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2009)...ariation believed to affect circadian rhythm, ,... New research suggests that an internal body clock...evelopment of bipolar disorder in children. , ...netic makeup of 152 children with bipolar disorder...swings, and 140 children without the disorder. The...
(Date:11/27/2009)...RD, Mass., Nov. 27 GSI G...upplier of precision technology products and semic...eeting of the Company,s shareholders has been sche...cation of the meeting will be announced in due cou...d a requisition notice from Stephen Bershad, a hol...
(Date:11/27/2009)... Biotech firm Replikins Ltd. today issued i...enomic data. It shows that the lethality of the v...uring the virus,s current outbreak in the spring o... 2.0 (s.d. 0.1). The H1N1 infectivity count, howev...Boston (PRWEB) November 27, 2009 -- Biotech firm R...
(Date:11/27/2009)...NCISCO, Nov. 27 The Gymb...lair Lambert, CFO/COO, will present at the NASDAQ ...he May Fair Hotel in London, England, on Wednesday...sten to a live broadcast of The Gymboree Corporati... to www.gymboree.com, click on "Our Company" at th...
(Date:11/27/2009)...LLY-SUR-SEINE, France, Nov. 27 Tea...al cycling team dedicated to ethical sporting and ...s, announced today that it will become Team Garmin...cal as a new sponsor of the team. Transitions Opti...e eyewear, offering the most advanced photochromic...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:GSI Group Calls Shareholders Meeting 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3
...s health plans in member satisfaction in four key ... Kaiser Permanente announced today that its member...n,s health plans highest in customer satisfaction ...west. These plans serve almost 7.5 million of Kai...
... include improved patient outcomes and , real-time... Somanetics Corporation (Nasdaq: SMTS ) announc... and Drug Administration (FDA) to expand the label...sed to manage therapies in patients above 2.5 kilo...
...l 16 Vion Pharmaceuticals, Inc. (OTC Bulletin Bo...ication (NDA) for its lead oncology therapeutic On...r review by the U.S. Food and Drug Administration ...gent for remission induction treatment for patient...
...Will Earn Decision Resources, Clinical Gold Standa...g to a New Report from Decision Resources , , WAL...the world,s leading research and advisory firms fo... that most influences their prescribing decisions ...
...and Vitamins Play an Important Role in Preventing ...rriors take note: Bursts of high-energy athletic a...lined by injury from overexertion. Overall wellnes...dy shows 91 percent of orthopedic specialists woul...
...d HIV business with the independence and sustainab...ment, access and shareholder value , - Renews focu... more new HIV treatments , - Equity split of 85% G...e entered into an agreement to create a new world-...
Other Medicine News:Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 2Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 3Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 4Health News:Somanetics Announces New FDA 510(K) Clearance 2Health News:Somanetics Announces New FDA 510(K) Clearance 3Health News:Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA 2Health News:Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA 3Health News:For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission 2Health News:For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission 3Health News:Video: Helping Weekend Warriors Stay in the Game 2Health News:Video: Helping Weekend Warriors Stay in the Game 3Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 2Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 3Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 4Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 5Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 6Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 7Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 8Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 9
(Date:11/25/2009)..., PRINCETON, N.J., Nov. 25 /PRNewswire-FirstCall/...stage pharmaceutical company committed to discover... treat viral infections, reported financial result... September 30, 2009 Pharmasset held $58.4 million ...ts. ,, Pipeline Update and 2009 Highlights ,...
(Date:11/25/2009)..., CHICAGO and STAFA, Switzerland, Nov. 25 /PRNewsw...manufacturer of innovative hearing solutions, pres...dults Conference, focusing on the special needs of...ther leading experts in aging and audiology from a...ork everyday with older people with hearing loss f...
(Date:11/25/2009)... BRIDGEWATER, N.J., Nov. 25 The FD... (etravirine) tablets, a non-nucleoside reverse tr...ly NNRTI specifically indicated for use in treatme...ic failure with HIV-1 strains resistant to an NNRT...itional approval is based on 48-week data from two...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5Soy in the Diet May Protect Lung Function 50201 1The Psychology of Celebrity Worship 50198 1The Psychology of Celebrity Worship 50198 2The Psychology of Celebrity Worship 50198 3CareFusion Names Robert Friel to Board of Directors 50196 1CareFusion Names Robert Friel to Board of Directors 50196 2CareFusion Names Robert Friel to Board of Directors 50196 3
...ta from two Phase 3 trials show clinical success r...ibiotic therapy, WELLESLEY HILLS, Mass., March 13... announced today the presentation of,a poster enti...y for,Treating Infected Diabetic Foot Ulcers: A Ra...rial of Pexiganan Cream." The poster will be,prese...
...S, March 12 Eli Lilly and Company,(NYSE: LLY ), ...mpany,practices as alleged by the Connecticut Atto...issued March 11, 2008., The tone and content of t...rently be taking Zyprexa to treat a life-threateni...ed no acknowledgement of the,seriousness of schizo...
Other Medicine Technology:MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection 2MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection 3MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection 4MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection 5Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release 2Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release 3Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release 4
PAP Microwell ELISA
...EG-9200 is a Windows 2000 PC based EEG with high p...e and software. EEG-9200 provides high quality per... in the sleep lab or EEG lab. Quality EEG recordin...ICU. Neurofax has high performance, high sensitivi...
...pact is the first magnetic stimulator to offer the...c stimulation. It is designed to provide the simpl...stic routine (at the same time, it may also help r...ions without moving away from your patient). , ,...
Fidelity IAB Intra-Aortic Balloon Catheter
Medicine Products: